文献速递心脑血管急症重症综合管理与镇静镇痛

血清胶质纤维酸性蛋白(GFAP)升高与心肺复苏后功能预后不良相关

Elevated Serum Glial Fibrillary Acidic Protein (GFAP) is Associated with Poor Functional Outcome After Cardiopulmonary Resuscitation.
PubMed 文献 · Neurocrit Care · 2017-01-01
一句话结论心脏骤停复苏后48小时血清GFAP>0.08 μg/L者均预后不良,GFAP>3 μg/L者均有严重脑损伤影像学表现,GFAP与NSE均为独立预测因子。

该前瞻性研究纳入100例心脏骤停复苏后患者,在复苏后48小时(容忍区间±12小时)采集血样,检测血清GFAP与NSE水平,主要终点为4周时改良格拉斯哥结局量表评分,低于4分定义为功能预后不良。预后不良组(n=61)GFAP中位数0.03 μg/L(四分位距0.01-0.07 μg/L),预后良好组(n=39)为0.02 μg/L(0.01-0.03 μg/L),p=0.014。GFAP预测预后不良的敏感度60.7%、特异度66.7%;所有GFAP>0.08 μg/L者均预后不良;GFAP>3 μg/L者均有严重脑损伤影像学表现。NSE预测预后不良的敏感度44.3%、特异度100.0%。多因素回归显示GFAP、NSE与Karnofsky指数均为结局的独立预测因子。

要点

  • 复苏后48小时(±12小时)血清GFAP>0.08 μg/L者全部(100%)预后不良,可作为床旁高危识别阈值。
  • GFAP>3 μg/L者均出现严重脑损伤的脑影像学表现,提示需重点评估神经损伤。
  • GFAP预测预后不良敏感度60.7%、特异度66.7%;NSE敏感度44.3%、特异度100.0%,两者释放模式不同。
  • 多因素回归显示GFAP、NSE与Karnofsky指数均为复苏后结局的独立预测因子,两者独立贡献于结局预测。
  • 预后不良组GFAP中位数0.03 μg/L(0.01-0.07 μg/L)高于预后良好组0.02 μg/L(0.01-0.03 μg/L),p=0.014。

适用人群与场景

  • 心脏骤停后心肺复苏成功、于复苏后48小时(容忍区间±12小时)纳入的前瞻性研究人群,共100例。
  • 主要终点为4周时改良格拉斯哥结局量表评分,低于4分定义为功能预后不良。

诊断标准与关键阈值

  • 功能预后不良定义:4周时改良格拉斯哥结局量表评分低于4分。
  • GFAP预测预后不良的阈值参考:GFAP>0.08 μg/L者全部预后不良;GFAP>3 μg/L者均有严重脑损伤的脑影像学表现。

红旗征与不能漏的情况

  • 复苏后48小时血清GFAP>0.08 μg/L提示预后不良(本研究中该水平以上者全部预后不良)。
  • 血清GFAP>3 μg/L者均存在严重脑损伤的脑影像学表现。

研究设计与关键结果

  • 前瞻性研究纳入100例心脏骤停复苏后48小时(±12小时)患者,采集血清检测GFAP与NSE,主要终点为4周改良格拉斯哥结局量表评分(低于4分为预后不良)。
  • 预后不良组(n=61)GFAP中位数0.03 μg/L(四分位距0.01-0.07 μg/L),预后良好组(n=39)0.02 μg/L(0.01-0.03 μg/L),p=0.014。
  • GFAP预测预后不良的敏感度60.7%、特异度66.7%;NSE敏感度44.3%、特异度100.0%。
  • 所有GFAP>0.08 μg/L者均预后不良;GFAP>3 μg/L者均有严重脑损伤的脑影像学表现。
  • 多因素回归分析显示GFAP、NSE与Karnofsky指数均为结局的独立预测因子。

证据类型、等级与局限

  • 证据类型:前瞻性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 复苏后48小时(±12小时)可检测血清GFAP与NSE,两者释放模式不同,均独立贡献于复苏后结局预测。
  • GFAP>0.08 μg/L者在本研究中全部预后不良,GFAP>3 μg/L者均有严重脑损伤影像学表现,可据此识别需重点神经评估的患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The neurological prognosis of patients after cardiopulmonary resuscitation (CPR) is difficult to assess. GFAP is an astrocytic intermediate filament protein released into bloodstream in case of cell death. We performed a prospective study aiming to compare the predictive potential of GFAP after resuscitation to the more widely used biomarker neuron-specific enolase (NSE).

METHODS: One hundred patients were included at 48 h (tolerance interval ±12 h) after cardiac arrest. A serum sample was collected immediately after study inclusion. We determined serum levels of GFAP and NSE by means of immunoassays. Primary outcome was the modified Glasgow outcome scale at 4 weeks. Values below four were considered as a poor functional outcome.

RESULTS: Median GFAP levels in poor outcome (n = 61) and good outcome (n = 39) patients were 0.03 μg/L (interquartile range 0.01-0.07 μg/L) and 0.02 μg/L (0.01-0.03 μg/L; p = 0.014), respectively. GFAP revealed a sensitivity of 60.7% and a specificity of 66.7% to predict a poor functional outcome. All patients having a GFAP level >0.08 µg/L had a poor functional outcome. For NSE, sensitivity was 44.3% and specificity was 100.0% for predicting a poor outcome. Multivariate regression analysis revealed GFAP, NSE, and the Karnofsky index to be independent predictors of outcome.

CONCLUSIONS: The release patterns of GFAP and NSE after CPR show differences. GFAP levels above 0.08 µg/L were associated with a poor outcome in all cases, and patients with strongly elevated values (>3 µg/L) consistently had severe brain damage on brain imaging. Both biomarkers independently contribute to outcome prediction after CPR.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Helwig K, Seeger F, Hölschermann H, et al. Elevated Serum Glial Fibrillary Acidic Protein (GFAP) is Associated with Poor Functional Outcome After Cardiopulmonary Resuscitation. Neurocrit Care. 2017. PMID: 28054291. doi:10.1007/s12028-016-0371-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。